Two new studies of people with autism spectrum disorder indicate that mosaic mutations and copy number variants contribute to a person's risk for the condition.
The methods, both published in Nature Biotechnology this week, result in completely phased haplotypes, without the need for sequencing parental samples.
Patients who underwent SLCO1B1 testing were able to lower their cholesterol levels similarly to those who did not, indicating that testing does not cause harm.
